- avoid unnecessary therapies
- obtain more detailed information about dose and effect
- measure quality of life and side effects of therapy
- assess additional examinations for their value
- disseminate the new findings through a worldwide network of collaborating study groups
- prolong life while preserving the quality of life
Cultural conditions and personal circumstances are always respected. Holistic treatment is provided – even in the event that study participation is discontinued.
The results of such studies are usually not available for several years, so the benefit to patients with breast cancer is not immediately apparent. A patient’s personal study data are always used in encrypted form for data protection.
ELEANOR study (Pierre Fabre): Neratinib for 1 year in hormone-sensitive, HER2-positive breast cancer, within 1 year of completion of anti-HER2 therapy. Phase IV Observational Study.
eMonarcHER trial (Lilly): Endocrine therapy + abemaciclib versus endocrine therapy + placebo in node-positive, hormone-sensitive, early-stage HER2-positive breast cancer.
EPIK-B3 study (Novartis): Alpelisib (BYL719) in combination with Nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation and/or PTEN loss without PIK3CA mutation.
EXPERT study (ANZ 1601/BIG 16-02): Adjuvant radiotherapy versus observation in breast-conserving and endocrine therapy of patients with molecularly characterized luminal A breast carcinoma (Prosigna® test).
IMPASSION 030 study (Roche): Atezolizumab (anti-PD-L1-AK) in combination with adjuvant chemotherapy (taxane/anthracycline-based) versus adjuvant chemotherapy alone in operable triple-negative breast cancer.
OPBC-02-/PREPEC-study: Prepectoral versus subpectoral implant breast reconstruction in skin-sparing or nipple-sparing mastectomy.
POLAR study (IBCSG 59/19): Palbociclib in hormone-sensitive, HER2-negative, isolated locoregional breast cancer recurrence.
TARGIT-B trial, UCL London Radiotherapy study: Intraoperative boost (IORT) versus conventional boost.
TAXIS trial (SAKK 23/16): Targeted versus radical axillary lymph node surgery followed by radiotherapy in patients with axillary lymph node metastases.
TOUCH trial (IBCSG 55-17): Neoadjuvant palbociclib plus letrozole and dual Her2 blockade versus paclitaxel plus dual Her2 blockade for postmenopausal patients with hormone-sensitive, Her2-positive breast carcinoma.
VISION I trial (SAKK 23-18): Vacuum-assisted biopsy immediately before surgery as an intraoperative or preoperative surrogate marker of tumor response to neoadjuvant chemotherapy. Currently interrupted due to change of sponsor.
HER2CLIMB-05 (Seagen): Tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer.
LidERA trial (Roche GO42784): Adjuvant endocrine therapy with giredestrant (oral SERD) vs endocrine therapy of choice for 5 years in hormone-sensitive, HER2-positive breast cancer.
SASKIA trial (Gilead): Postneoadjuvant study evaluating sacituzumab govitecan in primary HER2-negative breast cancer at increased risk of recurrence with incomplete pathologic remission after neoadjuvant chemotherapy.
SERENA 4 trial (Astra Zeneca): Camizestrant (oral SERD) + palbociclib + anstrazole placebo vs. anastrazole + palbociclib + SERD placebo in hormone-sensitive, HER2-negative metastatic breast cancer.
WISE study (IBCSG 95-17): 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy.
REDUSE trial (SAKK 96/12): Denosumab trial, denosumab 1-monthly versus 3-monthly in metastatic breast carcinoma with ≥ 3 bone metastases.
POSITIVE study (IBCSG 48/14): Study for patients of childbearing potential after 1.5-2.5 years of endocrine therapy.
SOFT trial (IBCSG 24/05) for premenopausal patients: Tamoxifen versus Tamoxifen with GnRH versus Aromasin with GnRH.
PALLAS study (ABCSG 42): Endocrine therapy +/- palbociclib (CDK4/6 inhibitor) for patients with hormone-sensitive breast carcinoma.
APHINITY trial: Neoadjuvant/herceptin and pertuzumab.
CATHERINE study: T-DM1 versus Herceptin in incomplete pathological remission after neoadjuvant chemotherapy.
TARGIT-A trial: Comparison of intraoperative radiation (IORT) alone with conventional radiotherapy.
TROG study: Radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.
ABCSG33R study: Axillary registry for sentinel LN metastases without axillary dissection.
SOLE study (IBCSG 35/07): for postmenopausal patients: extended anti-hormonal therapy with Femara after 4-6 years of endocrine therapy.
SENTINEL trial (IBCSG 23/09): for micrometastases in sentinel lymph nodes: Axillary dissection versus no axillary dissection.
TACHOSIL study (SAKK 23/13): procoagulant patch (Tachosil®) in the context of axillary dissection for seroma reduction (+/- fibrinogen patch insertion axillary).
SKINI study: prospective evaluation of radicality of breast tissue removal with skin- or nipple-sparing breast removal.
OncotypeDX study (SAKK 26/10): impact of Recurrence Score on adjuvant treatment recommendations for patients.
PRIME study: prospective study to determine the impact of MammaPrint on adjuvant treatment of hormone-sensitive, Her2-negative breast cancer.
ALTTO study (IBCSG 36-07) (adj. chemotherapy + Herceptin and/or lapatinib).
NEOSPHERE- and TRYPHAENA trial (Roche): neoadjuvant chemotherapy/herceptin/pertuzumab.
PREFHER trial (Roche): adjuvant Herceptin intravenous versus subcutaneous.
Elderly study (SAKK 25/14): lower-dose eribulin as first-line therapy in pat. ≥ 70 years.
Consilium study: symptom recording via smartphone app (OnkoZentrum Zürich).
KAITLIN study (Roche): Adjuvant chemotherapy/T-DM1/Herceptin/Pertuzumab.